Skip to content

Research at St Andrews

1-(Benzo[d]thiazol-2-yl)-3-phenylureas as dual inhibitors of casein kinase 1 and ABAD enzymes for treatment of neurodegenerative disorders

Research output: Contribution to journalArticlepeer-review


Ondrej Benek, Lukas Hroch, Laura Aitken, Frank Gunn-Moore, Lucie Vinklarova, Kamil Kuca, Daniel I. Perez, Concepcion Perez, Ana Martinez, Zdenek Fisar, Kamil Musilek

School/Research organisations


Several neurodegenerative disorders including Alzheimer’s disease (AD) have been connected with deregulation of casein kinase 1 (CK1) activity. Inhibition of CK1 therefore presents a potential therapeutic strategy against such pathologies. Recently, novel class of CK1-specific inhibitors with N-(benzo[d]thiazol-2-yl)-2-phenylacetamide structural scaffold has been discovered. 1-(benzo[d]thiazol-2-yl)-3-phenylureas, on the other hand, are known inhibitors amyloid-beta binding alcohol dehydrogenase (ABAD), an enzyme also involved in pathophysiology of AD. Based on their tight structural similarity, we decided to evaluate series of previously published benzothiazolylphenylureas, originally designed as ABAD inhibitors, for their inhibitory activity towards CK1. Several compounds were found to be submicromolar CK1 inhibitors. Moreover, two compounds were found to inhibit both, ABAD and CK1. Such dual-activity could be of advantage for AD treatment, as it would simultaneously target two distinct pathological processes involved in disease’s progression. Based on PAMPA testing both compounds were suggested to permeate the blood-brain barrier, which makes them, together with their unique dual activity, interesting lead compounds for further development.


Original languageEnglish
Pages (from-to)665-670
Number of pages6
JournalJournal of Enzyme Inhibition and Medicinal Chemistry
Issue number1
Early online date14 Mar 2018
Publication statusPublished - 2018

    Research areas

  • Alzheimer's disease, Amyloid-beta binding alcohol dehydrogenase (ABAD), Benzothiazole, Casein kinase 1 (CK1), Neurodegeneration

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Neuroprotective actions of leptin facilitated through balancing mitochondrial morphology and improving mitochondrial function

    Cheng, Y., Buchan, M., Vitanova, K., Aitken, L., Gunn-Moore, F. J., Ramsay, R. R. & Doherty, G., 13 Oct 2020, In: Journal of Neurochemistry. 155, 2, p. 191-206 e15003.

    Research output: Contribution to journalArticlepeer-review

  2. Benzothiazolyl ureas are low micromolar and uncompetitive inhibitors of 17β-HSD10 with implications to Alzheimer’s disease treatment

    Schmidt, M., Benek, O., Vinklarova, L., Hrabinova, M., Zemanova, L., Chribek, M., Kralova, V., Hroch, L., Dolezal, R., Lycka, A., Prchal, L., Jun, D., Aitken, L., Gunn-Moore, F., Kuca, K. & Musilek, K., 17 Mar 2020, In: International Journal of Molecular Sciences. 21, 6, 26 p., 2059.

    Research output: Contribution to journalArticlepeer-review

  3. Novel benzothiazole-based ureas as 17β-HSD10 inhibitors, a potential Alzheimer’s disease treatment

    Aitken, L., Benek, O., McKelvie, B., Hughes, R. E., Hroch, L., Schmidt, M., Major, L. L., Vinklarova, L., Kuca, K., Smith, T. K., Musilek, K. & Gunn-Moore, F. J., 29 Jul 2019, In: Molecules. 24, 15, 2757.

    Research output: Contribution to journalArticlepeer-review

  4. In vitro assay development and HTS of small molecule human ABAD/17β-HSD10 inhibitors as therapeutics in Alzheimer’s Disease

    Aitken, L., Baillie, G., Pannifer, A., Morrison, A., Jones, P. S., Smith, T. K., McElroy, S. P. & Gunn-Moore, F. J., Jul 2017, In: SLAS Discovery. 22, 6, p. 676-685 11 p.

    Research output: Contribution to journalArticlepeer-review

  5. 6-benzothiazolyl ureas, thioureas and guanidines are potent inhibitors of ABAD/17β-HSD10 and potential drugs for Alzheimer's disease treatment: design, synthesis and in vitro evaluation

    Benek, O., Hroch, L., Aitken, L., Dolezal, R., Guest, P., Benkova, M., Soukup, O., Musil, K., Hughes, R., Kuca, K., Smith, T. K., Gunn-Moore, F. & Musilek, K., Jun 2017, In: Medicinal Chemistry. 13, 4, p. 345-358 14 p.

    Research output: Contribution to journalArticlepeer-review

Related by journal

  1. The preparation, in vitro screening and molecular docking of symmetrical bisquaternary cholinesterase inhibitors containing a but-(2E)-en-1,4-diyl connecting linkage

    Musilek, K., Pavlikova, R., Marek, J., Komloova, M., Holas, O., Hrabinova, M., Pohanka, M., Dohnal, V., Dolezal, M., Gunn-Moore, F. J. & Kuca, K., 2011, In: Journal of Enzyme Inhibition and Medicinal Chemistry. 26, 2, p. 245-253

    Research output: Contribution to journalArticlepeer-review

ID: 252361017